747 related articles for article (PubMed ID: 31980173)
1. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
2. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K
Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203
[No Abstract] [Full Text] [Related]
3. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
4. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
5. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
6. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer.
Ao X; Yang Y; Li W; Tan Y; Guo W; Ao L; He X; Wu X; Xia J; Xu X; Guo J
J Immunother; 2019 Oct; 42(8):284-296. PubMed ID: 31261167
[TBL] [Abstract][Full Text] [Related]
7. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
[TBL] [Abstract][Full Text] [Related]
8. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
9. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
Front Immunol; 2021; 12():628906. PubMed ID: 33777013
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models.
Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
[TBL] [Abstract][Full Text] [Related]
12. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
13. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
14. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
15. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
Zhang Z; Jiang D; Yang H; He Z; Liu X; Qin W; Li L; Wang C; Li Y; Li H; Xu H; Jin H; Qian Q
Cell Death Dis; 2019 Jun; 10(7):476. PubMed ID: 31209210
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
[TBL] [Abstract][Full Text] [Related]
17. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
[TBL] [Abstract][Full Text] [Related]
18. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
[TBL] [Abstract][Full Text] [Related]
19. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
20. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.
Schoutrop E; Poiret T; El-Serafi I; Zhao Y; He R; Moter A; Henriksson J; Hassan M; Magalhaes I; Mattsson J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]